Novo Nordisk Resubmits Biologics License Application to FDA for Awiqli to Treat Type 2 Diabetes-February 2024-www.financetom.com

Novo Nordisk Resubmits Biologics License Application to FDA for Awiqli to Treat Type 2 Diabetes

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Novo Nordisk Resubmits Biologics License Application to FDA for Awiqli to Treat Type 2 Diabetes

Sep 29, 2025 7:10 AM

09:27 AM EDT, 09/29/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Monday that it has resubmitted its biologics license application to the US Food and Drug Administration for Awiqli to treat patients with type 2 diabetes.

The Danish pharmaceutical company said the resubmission of the once-weekly injection of the basal insulin treatment is based on a phase 3a trial of Awiqli.

Shares of Novo Nordisk ( NVO ) were down 3% in recent premarket activity Monday.

Price: 53.90, Change: -1.71, Percent Change: -3.07

Previous page： Hope to get regulatory approval for Sputnik V in India by January: RDIF Next page： HC declines to entertain 'half-baked' plea for immediate lockdown in Delhi

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Hope to get regulatory approval for Sputnik V in India by January: RDIF

Nov 20, 2020

Russia has said that its Sputnik V vaccine is proving to be 92 percent effective and President Vladimir Putin has suggested that India and China could start manufacturing the Sputnik V vaccine.

HC declines to entertain 'half-baked' plea for immediate lockdown in Delhi

Nov 23, 2020

Delhi government additional standing counsel Gautam Narayan, during the brief hearing, told the bench that there is a specific direction from the central government to all states and Union Territories that no lockdown be imposed without its permission.

DGCA extends suspension of scheduled international commercial passenger flights to Dec 31

Nov 26, 2020

”In partial modification of circular dated 26.6.2020, the competent authority has further extended the validity of circular issued on the subject cited above regarding scheduled international commercial passenger services to/from India till 2359 hours (IST) of December 31, 2020,” the DGCA said in the circular.

Byju's raising $200 million funding from BlackRock, T Rowe Price, say sources

Nov 22, 2020

The development comes about two months after Byju's had raised about $ 500 million (about Rs 3,672 crore) in a round that valued the company at $10.8 billion.